(Q38184833)

30 August 2017

HCC therapies--lessons learned (English)

1 reference

30 August 2017

hepatocellular carcinoma

1 reference

1 reference

Marcus-Alexander Wörns

series ordinal

1

1 reference

30 August 2017

Peter Robert Galle

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

4 February 2014

1 reference

Nature Reviews Gastroenterology & Hepatology

30 August 2017

1 reference

30 August 2017

11

1 reference

30 August 2017

447-452

1 reference

30 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2014.10

30 August 2017

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Systemic therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Novel inhibitors in development for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Systemic therapy and synergies by combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Future perspectives in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Novel therapeutics in hepatocellular carcinoma: how can we make progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Genomics and signaling pathways in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Real-time liquid biopsy in cancer patients: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Fighting the bushfire in HCC trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.10

31 March 2020

Identifiers

DOI

10.1038/NRGASTRO.2014.10

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference